Market Research Logo

Global Clostridium Difficile Treatment Market 2017-2021

Global Clostridium Difficile Treatment Market 2017-2021

About Clostridium Defficile Treatment

CDI is a bacterium that can cause symptoms such as diarrhea and life-threatening inflammation of the colon. CDI mostly affects elderly people who frequent hospitals or people who live in long-term care facilities. CDI can also occur due to the prolonged use of antibiotics. The first line of treatment for CDI is antibiotics.

Technavio’s analysts forecast the global clostridium defficile treatment market to grow at a CAGR of 5.14% during the period 2017-2021. Covered in this report

The report covers the present scenario and the growth prospects of the global clostridium defficile treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

· Americas

· APAC

· EMEA

Technavio's report, Global Clostridium Defficile Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors



    · Actelion Pharmaceuticals

    · Merck

    · Pfizer

    · Summit Therapeutics
Other prominent vendors


    · Astellas Pharma

    · CRESTOVO

    · Da Volterra

    · Immuron

    · MGB Biopharma

    · Novartis

    · Otsuka Pharmaceutical

    · Rebiotix

    · Romark Laboratories

    · Sanofi Pasteur

    · Seres Therapeutics

    · Shire

    · Synthetic Biologics

    · Valeant Pharmaceuticals

    · Valneva
Market driver
  • Rise in aging population
  • For a full, detailed list, view our report
Market challenge
  • High cost of therapy and high mortality rate
  • For a full, detailed list, view our report
Market trend
  • Special designation
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Clostridium Defficile Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global clostridium defficile treatment market: Actelion Pharmaceuticals, Merck, Pfizer, and Summit Therapeutics.

Other Prominent Vendors in the market are: Astellas Pharma, CRESTOVO, Da Volterra, Immuron, MGB Biopharma, Novartis, Otsuka Pharmaceutical, Rebiotix, Romark Laboratories, Sanofi Pasteur, Seres Therapeutics, Shire, Synthetic Biologics, Valeant Pharmaceuticals, and Valneva.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is special designation. Special designations such as Fast Track and Qualified Infectious Disease Product (QIDP), which are provided by the FDA, will encourage vendors to launch new products. These designations are beneficial for the market as they will enable the quick completion of the clinical trial process.”

According to the report, one driver in the market is rise in aging population. As people age, their immune systems deteriorate. People above the age of 60 may experience several medical complications. Aging plays a significant role in the manifestation of CDI. Research studies estimate that people above the age of 60 are susceptible to CDI, with the median age of diagnosis being 70. The rise in the aging population will increase the number of people affected by CDI.

Further, the report states that one challenge in the market is high cost of therapy and high mortality rate. CDI requires constant monitoring and medication, which leads to the increased use of antibiotics. Considering these antibiotics are expensive and have several side effects, patients end up discontinuing treatment. This leads to reduced patient adherence and shrinking the market value. The morbidity, mortality, and medical care costs of CDI have been growing.

Companies Mentioned

Actelion Pharmaceuticals, Merck, Pfizer, and Summit Therapeutics

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Overview
      • Table CDI: Symptoms
      • Table Various causes of CDI
  • Pipeline landscape
    • Table Global CDI treatment market: Key pipeline molecules by vendors 2016
    • Table Key clinical trials
  • Market landscape
    • Overview
      • Table Global CDI treatment market: Overview
    • Market size and forecast
      • Table Global CDI treatment market 2016-2021 ($ million)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug category
    • Table Global CDI treatment market: Segmentation by drug category 2016
    • Narrow spectrum antibiotic
      • Table Global CDI narrow spectrum antibiotics market 2016-2021 ($ million)
    • Broad spectrum antibiotics
      • Table Global CDI broad spectrum antibiotics market 2016-2021 ($ million)
  • Geographical segmentation
    • Table Global CDI treatment market: Segmentation by geography 2016 and 2021 (% share)
    • Table Global CDI treatment market: Revenue by geography 2016-2021 ($ million)
    • Americas
      • Table Americas: Overview
      • Table CDI treatment market in Americas 2016-2021 ($ million)
    • EMEA
      • Table EMEA: Overview
      • Table CDI treatment market in EMEA 2016-2021 ($ million)
    • APAC
      • Table APAC: Overview
      • Table CDI treatment market in APAC 2016-2021 ($ million)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Drugs under development
    • Market challenges
  • Market trends
    • Emergence of vaccines
      • Table Vaccines in development stage
    • Special designation
      • Table Companies that have benefited from special designations
    • Drug candidates with strong MOA
  • Vendor landscape
    • Competitive scenario
      • Table Global CDI treatment market: Competitive structure analysis 2016
      • Table Global CDI treatment market: Strategic success factors of companies
  • Key vendor analysis
    • Actelion Pharmaceuticals
      • Table Actelion: Key highlights
      • Table Actelion: Strength assessment
      • Table Actelion: Strategy assessment
      • Table Actelion: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Summit Therapeutics
      • Table Summit Therapeutics: Key highlights
      • Table Summit Therapeutics: Strength assessment
      • Table Summit Therapeutics: Strategy assessment
      • Table Summit Therapeutics: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report